Company profile
Xeris Biopharma Holdings, Inc.
NASDAQ: XERS · Healthcare · Biotechnology
#255 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
64CFH 75DQ 51GM 57SS 68
v0.1 · 65/100 weight · provisional
↑ Piotroski F, operating margin · ↓ growth stability, disclosure history
Methodology →Revenue TTM
$314.9M
Rev growth YoY (TTM)
+41.5%
Net income (FY)
$554.0k
Employees
435
as of 2026-08-09
Market cap
$1.4B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$291.8M$291.8M2025
Net income$554.0k$554.0k2025
Operating income$24.9M$24.9M2025
Total assets$383.5M$383.5M2025
Liabilities$369.8M$369.8M2025
Equity$13.7M$13.7M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY22
FY23
FY23
FY23
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product85%
Keveyis14%
Product, Other1%
By geography
Not disclosed.
The read
What is Xeris Biopharma Holdings, Inc.’s revenue?
Xeris Biopharma Holdings, Inc. booked $291.8M in FY2025 revenue, growing 44% year over year — faster than most Healthcare companies we track, at a 0.2% net margin.
Peers · Healthcare
Inogen, Inc.71BRigel Pharmaceuticals, Inc.82B+AngioDynamics, Inc.——Aurinia Pharmaceuticals Inc.78B+Adaptive Biotechnologies Corporation68BVericel Corporation83B+Neighbors
Cook →Key facts
CEOJohn Shannon
SectorHealthcare
IndustryBiotechnology
HeadquartersChicago, IL
ExchangeNASDAQ: XERS
Employees435
IPO date2018-06-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.